Comparing QL1206 to Prolia for postmenopausal osteoporosis
Part of Bones, joints & muscles clinical trials.
This trial tests a new medication, QL1206, against an approved drug, Prolia, to see if it works as well for treating osteoporosis in postmenopausal women. You may be eligible if you have low bone density and at least one risk factor for fractures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman who has gone through menopause (not had a period for more than 2 years or had both ovaries removed more than 2 years ago).
- You are between 50 and 85 years old and can walk on your own.
- You have low bone density in your spine or hip (T-score between -2.5 and -4.0).
- You have at least one of these risk factors: a past bone fracture from a minor fall (after age 40), a parent who broke a hip, high bone turnover, low body weight (BMI 19 or less), age 65 or older, or current smoking.
- You have not used certain osteoporosis medications like denosumab, bisphosphonates (for over 3 years), fluoride, or strontium within the last 5 years or within specific timeframes.
- You do not have other bone or metabolic diseases, kidney problems, vitamin D deficiency, dental issues needing surgery, or a history of more than two spine fractures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.
This study compares two treatment plans for women with osteoporosis to see which one improves hip bone density more. Participants will either get two medications in sequence (romosozumab followed by denosumab) or one medication (zoledronic acid), both given as injections or infusions. The goal is to find a treatment that reduces fracture risk.
This study tests a new injectable medication called SAL056 to strengthen bones and prevent fractures in postmenopausal women with osteoporosis. Researchers want to find the best dose and how often to give it.
This study looks at what changes in the body after starting romosozumab (an osteoporosis treatment) in postmenopausal women at higher risk for fractures. Researchers want to understand the treatment’s “mechanism,” which may help improve future osteoporosis care.
This trial studies AGN1 LOEP, a treatment being tested to improve bone strength in people with osteoporosis-related bone loss in the hip. If you qualify, you would be followed over time with clinic visits and testing to see how the treatment affects your bone health.
Hear when a new Postmenopausal Women With Osteoporosis at High Risk of Fracture trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.